Back Bay Life Science Report - MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds

MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds

10/13/21 • 26 min

“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.” - Jonathan P. Gertler, MD

For years, biotech has been the dominant theme in life sciences development, offering a great deal in treatment advances and in terms of investing versatility and returns potential. But with promising system solutions serving broader swaths of patients, medtech is resurging.

Medtech investment has grown dramatically over time, with scale and diversification capable of weathering economic storms and fueling expansion in the markets.

Medtech is a significant driver of our healthcare economy, contributing to more meaningful patient care solutions and technology that continue to move care further from the hospital and more toward the home.

In this episode of The Life Science Report, Back Bay Life Science Advisors’ industry podcast, Dr. Jonathan Gertler speaks with Paul LaViolette Managing Partner & COO, SV Health Investors about the varying elements of medtech investments, including structured deals and strategies, the regulatory changes that are driving medtech forward and how more cost-effective care will be a turning point for granting access to more and more patients.

Topics in this podcast include:

The role of investment in medtech and how to match capital to the asset or company
Why “incremental" is a four-letter word in the world of venture
How medtech is a systems solution provider, which differs from biotech as a disease modifier based on increasing patient segmentation
How structured deals, traditionally the territory of biotech, have found their way deeply into medtech M&A and how the public markets are offering alternatives in a more robust way than recent history has shown
The regulatory changes for medtech in Europe and the profound impact this has on how investors and buyers make decisions

Subscribe to our industry podcast, The Life Science Report, and follow Back Bay Life Science Advisors on LinkedIn. Thank you for joining us.

“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.” - Jonathan P. Gertler, MD

Medtech investment has grown dramatically over time, with scale and diversification capable of weathering economic storms and fueling expansion in the markets.

Topics in this podcast include:

The role of investment in medtech and how to match capital to the asset or company
Why “incremental" is a four-letter word in the world of venture
How medtech is a systems solution provider, which differs from biotech as a disease modifier based on increasing patient segmentation
How structured deals, traditionally the territory of biotech, have found their way deeply into medtech M&A and how the public markets are offering alternatives in a more robust way than recent history has shown
The regulatory changes for medtech in Europe and the profound impact this has on how investors and buyers make decisions

Subscribe to our industry podcast, The Life Science Report, and follow Back Bay Life Science Advisors on LinkedIn. Thank you for joining us.

Previous Episode

Remote Patient Monitoring

One of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. Just ahead of the pandemic, investment in patient monitoring was booming; priming the system for quick uptake and innovation. As with vaccines, much groundwork had been done to prepare for dramatic innovation and widespread, rapid patient use, seemingly “overnight.”

In this episode of Back Bay Life Science Advisors' industry podcast, Drs. Jonathan Gertler and Corinne Nawn discuss the clinical considerations of remote patient monitoring, including advances in sensing platforms, wearables, and the current investment landscape driving the innovations allowing patients and physicians to interact meaningfully and safely from different locations.

Topics in this podcast include:

Investment in digital healthcare companies
- The spectrum of financings, acquisitions, IPOs, and SPACs in this space
New ways of patient monitoring through wearable tech
Understanding the details of sensing and capturing
Coordinating care based on analytics
Company partnerships and/or acquisitions

Read about MedTech's ascendance from Jonathan Gertler here.

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

Next Episode

Cell and Gene Therapy Investment Trends

Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear their discussion on emerging investment themes and which ones were key topics of discussion at this year’s conference.

Topics include:

The next generation of gene-editing technology
- CRISPR 2.0
- Off-target effects
- Novel nucleases
- PAM sequences
Autologous and Allogeneic CAR-T cell therapy
- Ex vivo vs. in vivo approaches
The business model on gene therapies
- Figuring out manufacturing capabilities first
- How to tap into larger markets
- Building businesses around small monogenic diseases

Learn more, read Bay Life Science Advisors' latest white paper on gene therapy innovation here.

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn.

Thank you for joining us.